Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit...

Related Keywords

Tianqing ,Zhejiang ,China ,Japan ,France ,Israel ,Daix ,Bourgogne ,South Korea ,Ukraine ,United States ,New York ,Paris ,France General ,Boston ,Massachusetts ,Russia ,Chinese ,French ,Pascaline Clerc ,Julia Cailleteau ,Aude Lepreux ,Sino Biopharm ,Chia Tai Tianqing Pharmaceutical Group Co Ltd ,Exchange Commission ,Data Monitoring Committee ,Brunswick Group ,Corporate Affairs ,Products Administration ,Health Care Conference ,Nasdaq ,Market Program ,Hepalys Pharma Inc ,Patricial Bank ,European Investment Bank ,Suspected Unexpected Serious Adverse Reaction ,Long Island City ,Euronext Paris ,Chief Executive Officer ,Hepalys Pharma ,Data Monitoring ,Investigational New Drug ,Medical Products Administration ,At The Market Program ,Hepalys License ,Informed Consent Form ,Patient First Visit ,Annual Health Care Conference ,Paris Hepatology Conference ,Annual Conference Liver Connect ,Nasdaq Global Market ,Roquet Montegon ,Private Securities Litigation Reform Act ,New Drug Application ,Universal Registration Document ,Des March ,Annual Report ,Half Year Report ,Markets ,